A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Clinical trial NCT03573310 · COMPLETED

Trial details

NCT number: NCT03573310
Sponsor: Janssen Research & Development, LLC
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Neoplasms Solid Tumor, Adult Non-Hodgkin Lymphoma Myelodysplastic Syndromes

Start date: 2018-07-13
Primary completion: 2025-09-25
Enrollment: 114

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.